NCT07499518Not yet recruiting
Fertility and Polycystic Ovary Syndrome
Description of Fertility and Pregnancies in Patients With Polycystic Ovary Syndrome
Source: ClinicalTrials.gov · Last updated 10 Jun 2026
Brief summary (registry, in English)
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of reproductive age and affects approximately 10% of women worldwide. The diagnosis is based on the Rotterdam criteria established in 2003 and updated in the latest recommendations from the European Society of Human Reproduction (ESHRE) in 2023. The diagnosis of PCOS is based on the presence of 2 of the following 3 criteria: 1. Oligo-anovulation 2. Clinical and/or biological hyperandrogenism 3. Polycystic ovary morphology (PCOM) on imaging It is also the leading cause of anovulatory infertility, with a 15-fold increased risk of infertility. It is therefore a major cause of anovulatory infertility, but its pathophysiological mechanisms remain complex and multifactorial, involving interactions between genetic, metabolic, hormonal, and environmental factors. Prior to embarking on a fertility treatment plan, it is essential to better understand how these various factors influence ovarian function and reproductive capacity in patients with PCOS. Identifying and characterizing factors associated with fertility-such as hormonal profiles, insulin sensitivity, and metabolic markers-could help better predict future fertility and optimize personalized care and fertility outcomes. The aim of this study is therefore to identify modifiable factors influencing the fertility of PCOS patients phenotyped at La Pitié-Salpêtrière hospital.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 473 (estimated)
- First submitted
- 24 Mar 2026
- Start date
- 1 Jun 2026
- Primary completion date
- 1 Jun 2027
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- NCT number
- NCT07499518
What you commit to
- Study type: Observational
- Planned participants: 473
- From 1 Jun 2026 to the primary completion date, 1 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- A prior diagnosis of type 1 or type 2 diabetes
- Use of hormonal therapy, oral antidiabetic medication, lipid-lowering medication, antihypertensive medication, corticosteroids, or spironolactone
Lab values
- Lack of data on BMI, insulin levels, and fasting blood glucose
Other
- A diagnosis of non-classical adrenal block
- Menopause or current pregnancy
- Patients who do not speak French
- Patients under legal guardianship, conservatorship, or curatorship
Who the study is looking for
- Aged between 18 and 45 years old
- Female with a diagnosis of PCOS according to ESHRE criteria
- Previouslu enrolled in METABOPK research
- Aged between 18 and 45 years old
- Female with normal metabolic and hormonal profiles
- Previouslu enrolled in METABOPK research
Age in the registry: 18 years to 45 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Endocrinology department, Pitié Salpêtrière hospital Coordinator of this site? Confirm its status | Paris | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.